Pentoxifylline, Inflammation, and Endothelial Function in HIV-Infected Persons: A Randomized, Placebo-Controlled Trial

Samir Gupta, Deming Mi, Michael P. Dubé, Chandan Saha, Raymond M. Johnson, James H. Stein, Matthias Clauss, Kieren Mather, Zeruesenay Desta, Ziyue Liu

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background:Untreated HIV may increase the risk of cardiovascular events. Our preliminary in vitro and in vivo research suggests that pentoxifylline (PTX) reduces vascular inflammation and improves endothelial function in HIV-infected persons not requiring antiretroviral therapy.Methods:We performed a randomized, placebo-controlled trial of PTX 400 mg orally thrice daily for 8 weeks in 26 participants. The primary endpoint was change in flow-mediated dilation (FMD) of the brachial artery after 8 weeks. Nitroglycerin-mediated dilation (NTGMD) and circulating markers of inflammation, cellular immune activation, coagulation, and metabolism were also assessed.Results:The difference in mean absolute change (SD) in FMD after 8 weeks between the placebo [-1.06 (1.45)%] and PTX [-1.93 (3.03)%] groups was not significant (P = 0.44). No differences in NTGMD were observed. The only significant between-group difference in the changes in biomarkers from baseline to week 8 was in soluble tumor necrosis factor receptor-1 (sTNFRI) [-83.2 pg/mL in the placebo group vs. +65.9 pg/mL in the PTX group; P = 0.03]. PTX was generally well-tolerated.Conclusions:PTX did not improve endothelial function and unexpectedly increased the inflammatory biomarker sTNFRI in HIV-infected participants not requiring antiretroviral therapy. Additional interventional research is needed to reduce inflammation and cardiovascular risk in this population.Trial Registration: ClinicalTrials.gov NCT00796822.

Original languageEnglish
Article numbere60852
JournalPLoS One
Volume8
Issue number4
DOIs
StatePublished - Apr 9 2013

Fingerprint

pentoxifylline
Pentoxifylline
placebos
Randomized Controlled Trials
inflammation
Placebos
HIV
Inflammation
Dilatation
Nitroglycerin
Biomarkers
biomarkers
therapeutics
Brachial Artery
tumor necrosis factors
Tumor Necrosis Factor Receptors
Coagulation
coagulation
endpoints
Research

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Pentoxifylline, Inflammation, and Endothelial Function in HIV-Infected Persons : A Randomized, Placebo-Controlled Trial. / Gupta, Samir; Mi, Deming; Dubé, Michael P.; Saha, Chandan; Johnson, Raymond M.; Stein, James H.; Clauss, Matthias; Mather, Kieren; Desta, Zeruesenay; Liu, Ziyue.

In: PLoS One, Vol. 8, No. 4, e60852, 09.04.2013.

Research output: Contribution to journalArticle

@article{fed9944dcd9c49048ac3161deaa13bad,
title = "Pentoxifylline, Inflammation, and Endothelial Function in HIV-Infected Persons: A Randomized, Placebo-Controlled Trial",
abstract = "Background:Untreated HIV may increase the risk of cardiovascular events. Our preliminary in vitro and in vivo research suggests that pentoxifylline (PTX) reduces vascular inflammation and improves endothelial function in HIV-infected persons not requiring antiretroviral therapy.Methods:We performed a randomized, placebo-controlled trial of PTX 400 mg orally thrice daily for 8 weeks in 26 participants. The primary endpoint was change in flow-mediated dilation (FMD) of the brachial artery after 8 weeks. Nitroglycerin-mediated dilation (NTGMD) and circulating markers of inflammation, cellular immune activation, coagulation, and metabolism were also assessed.Results:The difference in mean absolute change (SD) in FMD after 8 weeks between the placebo [-1.06 (1.45){\%}] and PTX [-1.93 (3.03){\%}] groups was not significant (P = 0.44). No differences in NTGMD were observed. The only significant between-group difference in the changes in biomarkers from baseline to week 8 was in soluble tumor necrosis factor receptor-1 (sTNFRI) [-83.2 pg/mL in the placebo group vs. +65.9 pg/mL in the PTX group; P = 0.03]. PTX was generally well-tolerated.Conclusions:PTX did not improve endothelial function and unexpectedly increased the inflammatory biomarker sTNFRI in HIV-infected participants not requiring antiretroviral therapy. Additional interventional research is needed to reduce inflammation and cardiovascular risk in this population.Trial Registration: ClinicalTrials.gov NCT00796822.",
author = "Samir Gupta and Deming Mi and Dub{\'e}, {Michael P.} and Chandan Saha and Johnson, {Raymond M.} and Stein, {James H.} and Matthias Clauss and Kieren Mather and Zeruesenay Desta and Ziyue Liu",
year = "2013",
month = "4",
day = "9",
doi = "10.1371/journal.pone.0060852",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Pentoxifylline, Inflammation, and Endothelial Function in HIV-Infected Persons

T2 - A Randomized, Placebo-Controlled Trial

AU - Gupta, Samir

AU - Mi, Deming

AU - Dubé, Michael P.

AU - Saha, Chandan

AU - Johnson, Raymond M.

AU - Stein, James H.

AU - Clauss, Matthias

AU - Mather, Kieren

AU - Desta, Zeruesenay

AU - Liu, Ziyue

PY - 2013/4/9

Y1 - 2013/4/9

N2 - Background:Untreated HIV may increase the risk of cardiovascular events. Our preliminary in vitro and in vivo research suggests that pentoxifylline (PTX) reduces vascular inflammation and improves endothelial function in HIV-infected persons not requiring antiretroviral therapy.Methods:We performed a randomized, placebo-controlled trial of PTX 400 mg orally thrice daily for 8 weeks in 26 participants. The primary endpoint was change in flow-mediated dilation (FMD) of the brachial artery after 8 weeks. Nitroglycerin-mediated dilation (NTGMD) and circulating markers of inflammation, cellular immune activation, coagulation, and metabolism were also assessed.Results:The difference in mean absolute change (SD) in FMD after 8 weeks between the placebo [-1.06 (1.45)%] and PTX [-1.93 (3.03)%] groups was not significant (P = 0.44). No differences in NTGMD were observed. The only significant between-group difference in the changes in biomarkers from baseline to week 8 was in soluble tumor necrosis factor receptor-1 (sTNFRI) [-83.2 pg/mL in the placebo group vs. +65.9 pg/mL in the PTX group; P = 0.03]. PTX was generally well-tolerated.Conclusions:PTX did not improve endothelial function and unexpectedly increased the inflammatory biomarker sTNFRI in HIV-infected participants not requiring antiretroviral therapy. Additional interventional research is needed to reduce inflammation and cardiovascular risk in this population.Trial Registration: ClinicalTrials.gov NCT00796822.

AB - Background:Untreated HIV may increase the risk of cardiovascular events. Our preliminary in vitro and in vivo research suggests that pentoxifylline (PTX) reduces vascular inflammation and improves endothelial function in HIV-infected persons not requiring antiretroviral therapy.Methods:We performed a randomized, placebo-controlled trial of PTX 400 mg orally thrice daily for 8 weeks in 26 participants. The primary endpoint was change in flow-mediated dilation (FMD) of the brachial artery after 8 weeks. Nitroglycerin-mediated dilation (NTGMD) and circulating markers of inflammation, cellular immune activation, coagulation, and metabolism were also assessed.Results:The difference in mean absolute change (SD) in FMD after 8 weeks between the placebo [-1.06 (1.45)%] and PTX [-1.93 (3.03)%] groups was not significant (P = 0.44). No differences in NTGMD were observed. The only significant between-group difference in the changes in biomarkers from baseline to week 8 was in soluble tumor necrosis factor receptor-1 (sTNFRI) [-83.2 pg/mL in the placebo group vs. +65.9 pg/mL in the PTX group; P = 0.03]. PTX was generally well-tolerated.Conclusions:PTX did not improve endothelial function and unexpectedly increased the inflammatory biomarker sTNFRI in HIV-infected participants not requiring antiretroviral therapy. Additional interventional research is needed to reduce inflammation and cardiovascular risk in this population.Trial Registration: ClinicalTrials.gov NCT00796822.

UR - http://www.scopus.com/inward/record.url?scp=84876021960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876021960&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0060852

DO - 10.1371/journal.pone.0060852

M3 - Article

C2 - 23593327

AN - SCOPUS:84876021960

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e60852

ER -